Whitehawk swoops in for five ADCs via development deal with China's Biocytogen
From the article
Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates using Biocytogen's discovery platform.
Continue reading on Fierce BiotechYou might also wanna read
Y-Biologics Secures U.S. Patent for Key ADC Antibody Co-Developed With Intocell
Seoul Economic Daily·1d ago
LG Chem Partners with Chinese Biotech to Develop Cancer Drugs
Seoul Economic Daily·1d ago
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
STAT·2d ago
CGT Catapult teams with Korecyte Bio on low-oxygen detecting CAR-T program
bioprocessintl.com·1mo ago
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
The Daily Upside·12d ago
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Bars·4d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.